ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CLGN vs RGNT // EV/EBITDA & P/E VALUATION

CollPlant Biotechnologies Ltd (NASDAQ) VS. Regentis Biomaterials Ltd. (NYSE) • 15-METRIC TALLY: CLGN 3 — RGNT 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLGN VS. RGNT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CLGN RGNT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 64.80% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -14.39% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 1/9 +4.00 CLGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.3 38.2 +18.11 CLGN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $12.7M $9.6M $3.1M CLGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CLGN REV RGNT REV CLGN GROSS % RGNT GROSS % CLGN FCF RGNT FCF
FY 2025 $2.4M $0 64.8% — -$9.4M -$1.4M
FY 2024 $515.0K $0 -50.0% — -$14.6M -$641.0K
FY 2023 $11.0M $0 — — -$2.8M -$1.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLGN // BETA —
RGNT // BETA —